The regulation of medical devices in AustraliaTGA Australia
The regulation of medical devices in Australia involves classifying devices based on their intended use and risk level. Higher risk devices undergo more rigorous assessment procedures to ensure they meet essential safety and performance principles before being approved for market. Ongoing monitoring is also conducted after devices enter the market to protect public health. The TGA regulates medical devices to confirm they are suitable for their intended purpose and that their benefits outweigh any risks when used correctly.
Medical Device Regulation (MDR) overview for Technion, May 25, 2021Levi Shapiro
On May 26, 2021, the EU introduced the most sweeping changes to the Medical Device legal framework since the mid 90's. Ulf Grundmann, Senior Partner, King & Spalding (Frankfurt), reviews some of these regulatory changes, from the perspective of medical device innovators. The presentation includes Scope and Definitions, Classification and Conformity Assessment, Placing a Device on the EU Market, UDI and EUDAMED, Supply Chain Obligations, PMS and Vigilance
The document provides an overview of clinical trials for medical devices. It discusses definitions of medical devices according to FDA and Indian regulations, and classification of devices into classes based on risk level. The key phases of medical device clinical trials are pilot/feasibility studies and pivotal/confirmatory studies. Other topics covered include premarket notification (510k), investigational device exemption (IDE), premarket approval (PMA), differences between device and drug trials, and the global and Indian medical device markets.
Presentation: Medical Devices: how to stay included workshop - Annual ReportsTGA Australia
Session 4: Annual Reports: This presentation discusses the requirements and importance of annual reports including information that is required by the TGA and recognising avoidable errors when writing an annual report.
TGA presentation: Postmarket MonitoringTGA Australia
View this presentation for information on:
what postmarket monitoring is and why it is important
tools used in postmarket monitoring, including risk management plans
managing risk and adverse events
the TGA's early warning system and recall actions.
The regulation of medical devices in AustraliaTGA Australia
The regulation of medical devices in Australia involves classifying devices based on their intended use and risk level. Higher risk devices undergo more rigorous assessment procedures to ensure they meet essential safety and performance principles before being approved for market. Ongoing monitoring is also conducted after devices enter the market to protect public health. The TGA regulates medical devices to confirm they are suitable for their intended purpose and that their benefits outweigh any risks when used correctly.
Medical Device Regulation (MDR) overview for Technion, May 25, 2021Levi Shapiro
On May 26, 2021, the EU introduced the most sweeping changes to the Medical Device legal framework since the mid 90's. Ulf Grundmann, Senior Partner, King & Spalding (Frankfurt), reviews some of these regulatory changes, from the perspective of medical device innovators. The presentation includes Scope and Definitions, Classification and Conformity Assessment, Placing a Device on the EU Market, UDI and EUDAMED, Supply Chain Obligations, PMS and Vigilance
The document provides an overview of clinical trials for medical devices. It discusses definitions of medical devices according to FDA and Indian regulations, and classification of devices into classes based on risk level. The key phases of medical device clinical trials are pilot/feasibility studies and pivotal/confirmatory studies. Other topics covered include premarket notification (510k), investigational device exemption (IDE), premarket approval (PMA), differences between device and drug trials, and the global and Indian medical device markets.
Presentation: Medical Devices: how to stay included workshop - Annual ReportsTGA Australia
Session 4: Annual Reports: This presentation discusses the requirements and importance of annual reports including information that is required by the TGA and recognising avoidable errors when writing an annual report.
TGA presentation: Postmarket MonitoringTGA Australia
View this presentation for information on:
what postmarket monitoring is and why it is important
tools used in postmarket monitoring, including risk management plans
managing risk and adverse events
the TGA's early warning system and recall actions.
IPO Fast Forward 2013: Medical Apps Event @ Maidstone & Tunbridge Wells NHS Trust. UK Medical Device regulator presentation from Rob Higgins, MHRA.gov.uk (Reproduced with permission)
The document summarizes the regulation of in vitro diagnostic (IVD) medical devices in Australia. It outlines the regulatory framework, classification system, conformity assessment process, and key aspects of an inclusion application for IVD devices to be entered into the Australian Register of Therapeutic Goods (ARTG). The summary highlights that IVD devices are regulated under the Therapeutic Goods Act and must comply with essential principles, be appropriately classified, and have evidence of conformity assessment submitted with ARTG applications, which may be subject to audit.
New EU Legislation on Medical Devices By G. Bos - BSI (Qserve Conference 2013)qserveconference2013
The document provides an overview of the proposed European Medical Device Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). It discusses timelines for implementation between 2013-2021, including designation of notified bodies. It describes the structure and key changes in the IVDR, including expanded definitions, increased control of the supply chain, new classification rules and routes for conformity assessment. Additional requirements are outlined for high-risk Class C and D devices, including a summary of safety and performance. Vigilance and clinical evidence reporting requirements are also strengthened under the new regulations.
This document provides an introduction to medical devices. It begins with definitions of medical devices as any instrument intended for medical use to diagnose, treat or alleviate disease or injury. Major groups of instruments are identified as surgical, dental/orthopedic, ophthalmology, implants and diagnostic devices. Classification of devices is described based on risk levels related to device type, duration of use, contact and anatomy. Variants and required materials information are outlined. Process validations are introduced as critical to ensuring consistent product quality and performance from batch to batch.
This 10-minute lecture gives a step-by-step instruction on medical device definition. It covers the basic definition of a medical device, its key attributes, and intended purpose. A brief insight is provided into in vitro diagnostic medical devices. At the end of this lecture, the student will be able to differentiate a medical device from pharmaceutical and biological healthcare products. The student will also be able to decide whether a particular healthcare product comes under the definition of a medical device.
http://semoegy.com
Regulatory Approval Process for Medical Devices in EU - Presentation by Aksha...Akshay Anand
A presentation on Regulatory Approval Process for Medical Devices in European Union that explains in brief about the various aspects including the EU Medical Device Directives, Classifications, CE Certification, Medical Device Registration & Timelines. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during January 2015
This document provides an overview of medical devices:
It defines medical devices as instruments used for medical purposes like diagnosis and treatment. The history section outlines important medical device innovations from the late 19th century to present. Regulations for medical devices are described, including organizations that regulate quality, safety and efficacy. Medical devices are classified based on their risks. The document discusses the drug development process, therapeutic and diagnostic uses of devices, risks, and concludes that benefits generally outweigh risks when proper risk management is followed.
Presentation: Medical Devices: how to stay included workshop - Adverse event ...TGA Australia
This presentation discusses adverse event reporting including identification and reporting of adverse events, recognising avoidable errors and the difference in reporting requirements for SAS and clinical trial devices.
TGA presentation: Lifecycle of a Medical Device / IVDTGA Australia
The document outlines the lifecycle of a medical device from clinical evidence and design through market supply and post-market activities. It notes requirements at each stage including clinical validation, regulatory approval, ongoing reporting, corrective actions and recalls. The lifecycle involves gathering clinical evidence, product development, pre-market review, post-market monitoring, and responding to issues through redesign or recalls when needed.
Materiovigilance programme of india by akhilesh sachanAkhilesh Sachan
The Materiovigilance Programme of India (MvPI) was launched in 2015 to study incidents related to medical devices and ensure patient safety. It allows dangerous devices to be removed from the market and defects to be addressed. The MvPI collects reports of device malfunctions, defects, or other issues directly from healthcare professionals and the public. It is coordinated by the Indian Pharmacopoeia Commission and Sree Chitra Tirunal Institute of Medical Sciences and Technology, with support from the National Health Systems Resource Centre. The program has established guidelines, forms, and monitoring centers to facilitate medical device safety surveillance in India.
This document discusses the process for bringing a mobile health application to market as a medical device in the European Union. It covers determining if the app meets the definition of a medical device, classifying the device, complying with applicable directives and standards, establishing a quality management system, and obtaining CE marking. The challenges of navigating this regulatory process for an existing app already in app stores are also addressed.
This document discusses regulations for medical devices in various countries and regions. It provides an overview of the regulatory bodies that oversee medical devices in Australia, Europe, the US, Canada, China, Japan, Brazil, and India. For the US, it describes the Food and Drug Administration's role and classifications of medical devices. It also summarizes key concepts around establishing registration and listing of devices, premarket notification (510(k)), de novo classification, premarket approval, and quality system regulations.
TGA presentation: medical devices audit assessmentsTGA Australia
An overview of the medical devices audit assessment process, including explanation about the difference between Level 1 and Level 2 audits and the information sponsors are generally required to provide.
TGA changes for Medical Devices in AustraliaJoe Hage
http://MedicalDevicesGroup.net Sydney-based regulatory affairs expert Arthur Brandwood discusses the recent changes made by the Australian Therapeutic Goods Administration (TGA).
He also covers:
• Australia’s aggressive deregulatory agenda
• The Australian tax incentive (43.5% for R&D expenditure)
• The simple process for regulation of clinical trials in Australia
• TGA’s web based submission process for device approvals
COVID-19 and the FDA: What Every Manufacturing Company Needs to KnowEMMAIntl
EMMA International Consulting Group provides quality, regulatory, and compliance consulting services for life sciences companies. The document discusses the FDA's temporary policies implemented in response to COVID-19. These policies aim to address medical device shortages by expediting approvals and allowing manufacturers to make modifications or distribute devices that were not previously approved. The FDA has issued guidance on hand sanitizers, ventilators, PPE, gowns/gloves, and reprocessing single-use devices. For devices not related to COVID-19, companies may face delays but the consulting group can help navigate regulatory issues.
Presentation: Regulation of personalised, including 3D printed, medical devicesTGA Australia
The status of making custom made devices exempt from registration is being looked at by TGA. But with the proliferation of 3D printing, we are getting more personalised medical devices. What is the right balance to enable innovation but having the right control to avoid major issues. This session is aimed at a more senior audience.
IPO Fast Forward 2013: Medical Apps Event @ Maidstone & Tunbridge Wells NHS Trust. UK Medical Device regulator presentation from Rob Higgins, MHRA.gov.uk (Reproduced with permission)
The document summarizes the regulation of in vitro diagnostic (IVD) medical devices in Australia. It outlines the regulatory framework, classification system, conformity assessment process, and key aspects of an inclusion application for IVD devices to be entered into the Australian Register of Therapeutic Goods (ARTG). The summary highlights that IVD devices are regulated under the Therapeutic Goods Act and must comply with essential principles, be appropriately classified, and have evidence of conformity assessment submitted with ARTG applications, which may be subject to audit.
New EU Legislation on Medical Devices By G. Bos - BSI (Qserve Conference 2013)qserveconference2013
The document provides an overview of the proposed European Medical Device Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). It discusses timelines for implementation between 2013-2021, including designation of notified bodies. It describes the structure and key changes in the IVDR, including expanded definitions, increased control of the supply chain, new classification rules and routes for conformity assessment. Additional requirements are outlined for high-risk Class C and D devices, including a summary of safety and performance. Vigilance and clinical evidence reporting requirements are also strengthened under the new regulations.
This document provides an introduction to medical devices. It begins with definitions of medical devices as any instrument intended for medical use to diagnose, treat or alleviate disease or injury. Major groups of instruments are identified as surgical, dental/orthopedic, ophthalmology, implants and diagnostic devices. Classification of devices is described based on risk levels related to device type, duration of use, contact and anatomy. Variants and required materials information are outlined. Process validations are introduced as critical to ensuring consistent product quality and performance from batch to batch.
This 10-minute lecture gives a step-by-step instruction on medical device definition. It covers the basic definition of a medical device, its key attributes, and intended purpose. A brief insight is provided into in vitro diagnostic medical devices. At the end of this lecture, the student will be able to differentiate a medical device from pharmaceutical and biological healthcare products. The student will also be able to decide whether a particular healthcare product comes under the definition of a medical device.
http://semoegy.com
Regulatory Approval Process for Medical Devices in EU - Presentation by Aksha...Akshay Anand
A presentation on Regulatory Approval Process for Medical Devices in European Union that explains in brief about the various aspects including the EU Medical Device Directives, Classifications, CE Certification, Medical Device Registration & Timelines. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during January 2015
This document provides an overview of medical devices:
It defines medical devices as instruments used for medical purposes like diagnosis and treatment. The history section outlines important medical device innovations from the late 19th century to present. Regulations for medical devices are described, including organizations that regulate quality, safety and efficacy. Medical devices are classified based on their risks. The document discusses the drug development process, therapeutic and diagnostic uses of devices, risks, and concludes that benefits generally outweigh risks when proper risk management is followed.
Presentation: Medical Devices: how to stay included workshop - Adverse event ...TGA Australia
This presentation discusses adverse event reporting including identification and reporting of adverse events, recognising avoidable errors and the difference in reporting requirements for SAS and clinical trial devices.
TGA presentation: Lifecycle of a Medical Device / IVDTGA Australia
The document outlines the lifecycle of a medical device from clinical evidence and design through market supply and post-market activities. It notes requirements at each stage including clinical validation, regulatory approval, ongoing reporting, corrective actions and recalls. The lifecycle involves gathering clinical evidence, product development, pre-market review, post-market monitoring, and responding to issues through redesign or recalls when needed.
Materiovigilance programme of india by akhilesh sachanAkhilesh Sachan
The Materiovigilance Programme of India (MvPI) was launched in 2015 to study incidents related to medical devices and ensure patient safety. It allows dangerous devices to be removed from the market and defects to be addressed. The MvPI collects reports of device malfunctions, defects, or other issues directly from healthcare professionals and the public. It is coordinated by the Indian Pharmacopoeia Commission and Sree Chitra Tirunal Institute of Medical Sciences and Technology, with support from the National Health Systems Resource Centre. The program has established guidelines, forms, and monitoring centers to facilitate medical device safety surveillance in India.
This document discusses the process for bringing a mobile health application to market as a medical device in the European Union. It covers determining if the app meets the definition of a medical device, classifying the device, complying with applicable directives and standards, establishing a quality management system, and obtaining CE marking. The challenges of navigating this regulatory process for an existing app already in app stores are also addressed.
This document discusses regulations for medical devices in various countries and regions. It provides an overview of the regulatory bodies that oversee medical devices in Australia, Europe, the US, Canada, China, Japan, Brazil, and India. For the US, it describes the Food and Drug Administration's role and classifications of medical devices. It also summarizes key concepts around establishing registration and listing of devices, premarket notification (510(k)), de novo classification, premarket approval, and quality system regulations.
TGA presentation: medical devices audit assessmentsTGA Australia
An overview of the medical devices audit assessment process, including explanation about the difference between Level 1 and Level 2 audits and the information sponsors are generally required to provide.
TGA changes for Medical Devices in AustraliaJoe Hage
http://MedicalDevicesGroup.net Sydney-based regulatory affairs expert Arthur Brandwood discusses the recent changes made by the Australian Therapeutic Goods Administration (TGA).
He also covers:
• Australia’s aggressive deregulatory agenda
• The Australian tax incentive (43.5% for R&D expenditure)
• The simple process for regulation of clinical trials in Australia
• TGA’s web based submission process for device approvals
COVID-19 and the FDA: What Every Manufacturing Company Needs to KnowEMMAIntl
EMMA International Consulting Group provides quality, regulatory, and compliance consulting services for life sciences companies. The document discusses the FDA's temporary policies implemented in response to COVID-19. These policies aim to address medical device shortages by expediting approvals and allowing manufacturers to make modifications or distribute devices that were not previously approved. The FDA has issued guidance on hand sanitizers, ventilators, PPE, gowns/gloves, and reprocessing single-use devices. For devices not related to COVID-19, companies may face delays but the consulting group can help navigate regulatory issues.
Presentation: Regulation of personalised, including 3D printed, medical devicesTGA Australia
The status of making custom made devices exempt from registration is being looked at by TGA. But with the proliferation of 3D printing, we are getting more personalised medical devices. What is the right balance to enable innovation but having the right control to avoid major issues. This session is aimed at a more senior audience.
EU MDR Preparation: Seize the Market Opportunity and Avoid the BottleneckApril Bright
The new EU Medical Device Regulation (MDR) is the single largest change to medical device regulations in Europe since the 1993 introduction of CE Marking. As grandfathering of existing products is not permitted, the new regulations affect all medical devices sold throughout Europe. There is a temptation for medical device companies to think that the transition arrangements through 1Q20 under MDR leave a considerable amount of time to ensure compliance. Research predicts that companies that do not address MDR early will suffer from potential bottlenecks among Notified Bodies for certification completion and capacity shortages by compliance professionals in the preparatory process. If you have not started to plan for the transition, now is the time to act. This presentation will take you through the main regulation changes and outline key requirements affecting manufacturers moving forward.
In the USA, medical devices are regulated by the Food and Drug Administration (FDA) with an aim to ensure safety and effectiveness of the devices. The Center for Devices and Radiological Health (CDRH) is an FDA component and looks after this program.
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
The document summarizes proposed regulatory reforms from the Therapeutic Goods Administration (TGA) Medical Devices Branch. It discusses proposed changes to the regulation of software as medical devices, personalized medical devices including 3D printed devices, essential principles, conformity assessment procedures, requirements for devices used in clinical trials, and clarifying requirements for systems and procedure packs. The proposed reforms aim to modernize regulations, increase alignment with international standards, and ensure oversight is risk-based and promotes safety. Public consultations will be held on the proposed changes.
Presentation: Conformity assessment evidenceTGA Australia
An overview of Conformity Assessment requirements and General Safety and Performance Requirements and demonstrating compliance in the Australian context.
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...Investnet
This document discusses the regulation of standalone software as a medical device. It begins by defining standalone software and noting the EU directive that amended the definition of a medical device to include software intended for medical purposes. It then covers how to qualify standalone software as a medical device and classify it. The document reviews essential requirements, harmonized standards, conformity assessment procedures including CE marking, and registration requirements. It provides advice for manufacturers on ensuring compliance and for users on reporting issues. The role of the Irish regulator HPRA in providing guidance and conducting oversight is also discussed.
PECB Webinar: Proposed changes for medical device quality management systems ...PECB
We will cover:
• Overview of proposed changes to ISO 13485:201X, MDSAP
• New EU regulations and unannounced audits
• New directions for QMS and regulatory audits
Presenter:
This webinar will be presented by Danny Kroo, the founder and principal consultant at Docusys Corporation.
This document summarizes recent EU regulatory developments in data protection, medical devices, and in vitro diagnostics. For medical devices, the proposal introduces stricter rules for clinical evaluations, notified body oversight, and transparency. It may introduce concepts of efficacy from pharmaceutical regulations. The in vitro diagnostics proposal significantly increases regulatory requirements, especially for higher risk devices. It aims to improve transparency through registration in a central EU database and making more clinical data publicly available.
This document summarizes recent EU regulatory proposals and developments regarding medical devices, in vitro diagnostics, and clinical trial data transparency. For medical devices, key proposals include stricter rules for notified bodies, more clinical data requirements, and alignment of some terminology with pharmaceuticals. For in vitro diagnostics, conformity assessment will depend more on risk class. Clinical trial data may become publicly available after marketing approval. Overall, the proposals aim to increase transparency but could significantly increase regulatory burden for these industries.
This document summarizes recent EU regulatory proposals and developments regarding medical devices, in vitro diagnostics, and clinical trial data transparency. For medical devices, key proposals include stricter rules for notified bodies, more clinical data requirements, and alignment of some terminology with pharmaceuticals. For in vitro diagnostics, conformity assessment will depend more on risk class. Clinical trial data may become publicly available after marketing approval. Overall, the proposals aim to increase transparency but could significantly increase regulatory burden for these industries.
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...TGA Australia
Session A4 - Medical Devices: Recall and non-recall actions of medical devices
Presented by:
Hugh Cameron, Head, Quality and Regulatory Affairs, BD
Mick O’Connor, Director, Recalls and Advertising, Office of Product Review, TGA
Joshan Joy, Recalls and Advertising, Office of Product Review, TGA
This document discusses regulations and standards that impact central service departments. It provides information on the differences between regulations and voluntary/regulatory standards. It reviews regulations from the FDA regarding medical device classification and labeling. It also discusses the roles of the CDC, DOT, EPA, and OSHA and how their regulations impact central service. Professional organizations that develop standards affecting central service are also reviewed.
Strategies for Device Approval in China, India, South Korea and AustraliaApril Bright
This session will describe the orthopaedic device regulatory and registration requirements in Asia Pacific markets. Regulatory steps and strategies will be presented for each of these countries. The discussion will also cover ways to gain regulatory information about competitors already selling in these markets. Attendees will leave the session with an understanding of timelines, costs and complexity for approval.
Changing PMA or HDE Devices during COVID-19EMMAIntl
As medical device firms adjust to the new normal in light of COVID-19 hurdles, the FDA continues to issue guidances and relax regulatory requirements to accommodate. Disruptions to global supplies and the challenge of social distance restrictions may be the driving forces behind necessary device and operations changes. Normally, the FDA requires manufacturers to file a supplement or 30-day notice for their premarket approvals (PMA) or humanitarian device exemptions (HDE) before implementing changes...
The document discusses the evolution and goals of the Unique Device Identification (UDI) system, which aims to uniquely identify medical devices and their attributes to improve safety. It outlines the roles of regulatory bodies like the FDA and IMDRF in developing UDI requirements. The UDI system is expected to benefit stakeholders by improving traceability, reducing errors, and enabling efficient recalls. However, implementing UDI presents challenges for medical device manufacturers related to integrating it into organizational processes and systems. Outsourcing partners with expertise in medical device engineering can help manufacturers implement UDI more quickly and cost-effectively.
Free webinar on Unique Device Identificationnykathlen
The document discusses planning and implementation of Unique Device Identification (UDI) requirements within the medical device industry. It outlines a six step process: 1) Developing a UDI compliance plan, 2) Understanding machine readable technology, 3) Managing change, 4) Conducting risk assessments, 5) Implementing UDI across the value chain, and 6) Identifying data sources for FDA reporting. It also provides an overview of compliance dates for UDI labeling and data submission requirements based on device class.
“CFDA Registration – Market Access Before Investment” delivered by Tim Lin, T...ulmedical
Due to a large population, increasing middle class and government plans to build tens of thousands of hospitals, there is a lot of demand for high quality medical devices in China. For many foreign medical device manufacturers, the regulatory barriers are still significant obstacles.
The medical device regulation in China is less harmonized and generally unique from other major markets. The primary challenges tend to be: actual testing, drafting standards, language barriers and license parking. These additional requirements create a delay in the registration process.
Foreign manufacturers need to specifically understand the Chinese medical device regulation in advance, and then are able to determine appropriate strategies aimed at successful China market entry.
This is the content for a live webinar, "CFDA Registration, Market Access before Investment...Solving the CFDA Challenge" delivered by UL's Tim Lin. Tim is the Senior Technical Consultant working in the Greater China Region. He majored in public health and medical device engineering, and worked as a reviewer in the Taiwan FDA for high and moderate-risk medical device and clinical trial protocol for over 5 years; and also drafted guidance for industry. He is now responsible for risk management file, usability engineering, software validation and CE MDD technical documentation.
introduction, classification, regulatory approval process for medical devices (510k) premarket notification, pre market approval (PMA), investigational device exemption (IDE) and invitro diagnostics, quality system requirements 21 CFR PART 820, labeling requirements 21 CFR part 801, UDI
Similar to Presentation: Custom-made medical devices: Information for the dental industry (20)
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...TGA Australia
The document discusses several regulatory reforms for listed medicines in Australia, including:
1. Permitted indications which provide a list of approved health benefit claims for listed medicines and require sponsors to select from this list, improving transparency.
2. An assessed listed pathway which allows pre-market evaluation of efficacy claims, providing access to higher-level health claims.
3. A "TGA assessed" label claim indicating the medicine's efficacy has been evaluated, improving consumer awareness and confidence.
4. Two years of market exclusivity for sponsors who apply for and are approved for new permitted ingredients.
Regulation, ethics and reimbursement of novel biological therapies in Austral...TGA Australia
The document provides an overview of novel biological therapies such as gene therapy, cell therapy, and tissue engineering in Australia. It discusses the regulatory pathways through the Therapeutic Goods Administration (TGA) for approval of these therapies. Clinical trials of novel biological therapies must be submitted through the CTX scheme for approval rather than just notification. Guidelines from the European Medicines Agency are a good resource for requirements for registration and approval of these therapies in Australia. Risks associated with gene therapy include potential for delayed adverse effects, off-target effects, insertional mutagenesis, and immune responses.
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
The document provides an overview of Australia's Good Manufacturing Practice (GMP) Clearance Framework. It discusses the legislative basis for manufacturing requirements, the roles and activities of the Manufacturing Quality Branch, and the two pathways for obtaining a GMP Clearance - a desk-based assessment through a Mutual Recognition Agreement or Compliance Verification, or an on-site TGA inspection. It also outlines the history of GMP Clearance, recognized authorities through agreements like MRAs, and the MRA assessment pathway.
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Presentation: The challenges of regulating direct to consumer digital medical...TGA Australia
The document discusses the challenges of regulating direct-to-consumer digital medical devices. It describes what digital medical devices are, including connected devices, telehealth, apps, and wearables. The Therapeutic Goods Administration (TGA) regulates medical devices in Australia to ensure they are safe and effective. However, digital devices pose new challenges as many are software-based and consumers may not understand their intended medical purpose. The TGA must determine how to appropriately apply existing regulations to these new technologies.
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
The document provides background information on Australia's Therapeutic Goods Advertising legislation and Code. It discusses key aspects of the legislation including:
- The Therapeutic Goods Act and Regulations set advertising requirements for therapeutic goods. Advertising must also comply with the Australian Consumer Law.
- The Act prohibits off-label promotion and requires pre-approval of medicine ads in certain media. It also places restrictions on advertising certain medical conditions.
- The Therapeutic Goods Advertising Code provides the framework for ensuring advertising is conducted properly and does not mislead consumers. It was recently revised to provide more clarity.
- The Code applies broadly to any advertising of therapeutic goods. It exempts genuine news reporting and ads directed to health
Webinar presentation: Consultation on reforms to the generic medicine market ...TGA Australia
The TGA is consulting on reforms to streamline the generic medicine market authorisation process. The proposed reforms include: 1) Reducing regulatory barriers such as relaxing requirements for dissolution data and reference products in bioequivalence studies. 2) Providing more certainty on data requirements through early advice on biowaiver justifications. 3) Supporting international work sharing by using common templates for bioequivalence studies and biowaiver justifications. 4) Prioritizing applications for generic medicines that address shortages or high expenditure to encourage more competition. Feedback is sought through an online consultation closing March 21. The reforms aim to enhance supply of affordable generic medicines in Australia.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Presentation: Custom-made medical devices: Information for the dental industry
1. Custom-made medical devices
Information for the dental industry
Valerie Mercer
Director Medical Devices Information and Education
Medical Devices Branch
Therapeutic Goods Administration
ADIA industry briefing 12-13 July 2016
2. Discussion topics
• Legislative framework
• What is custom-made?
• Notifying TGA
• Regulatory obligations
- pre-market
- post-market
ADIA industry briefing 12-13 July 2016 1
3. Regulatory framework
Commonwealth legislation
• Therapeutic Goods Act 1989
especially Chapter 4 Medical Devices
• Therapeutic Goods (Medical Devices)
Regulations 2002
• https://www.tga.gov.au/legislation-legislative-instruments
ADIA industry briefing 12-13 July 2016 2
7. Definitions
Custom-made medical device
• the Regulations define
a custom-made medical
device as ….
• examples relevant to the
dental industry may include:
- crowns
- bridges
- dentures
- specialised instruments
ADIA industry briefing 12-13 July 2016 6
8. ‘Customised’ does not equal a custom-made
medical device
• an existing medical device that is adapted, altered, fashioned, modified or ‘customised’ to fit a patient is
NOT a custom-made medical device
• for example, a preformed permanent dental crown
that may require minimal fashioning in situ during
restorative work is not a custom-made medical device
• devices already included on the ARTG that are combined
and adapted for an individual (provided the devices are
used as intended by the manufacturer/IFUs) are not
custom-made medical devices (orthodontic braces)
ADIA industry briefing 12-13 July 2016 7
10. Definitions
Sponsor
• s3 of the Act defines
a sponsor as …
• sometimes the sponsor and the
manufacturer are the same entity
e.g. a dental laboratory that
supplies their products directly
to dental professionals
• dentists and allied oral healthcare
providers can import custom-made
devices from overseas, but in doing
so they become the sponsor and
acquire obligations
9
11. Definitions
Kinds of devices
• s41BE of the Act defines
kinds of medical devices as …
• TGA needs to be notified of each
kind of device
• TGA does not need to be notified
about each individual device being
made for individual patients
ADIA industry briefing 12-13 July 2016 10
12. Kinds of medical devices - examples
Example 1
Dentist (sponsor) imports polymer dental bridges
manufactured by Manufacturer A in China:
- same sponsor
- same manufacturer
- same GMDN code
- same classification
Therefore same kind of medical device and only
one notification to TGA required.
Do not need to notify TGA for each patient
receiving a custom-made medical device of this
kind.
Example 2
Dentist (sponsor) imports polymer dental bridges
manufactured by Manufacturer A in China and
Manufacturer B in Germany:
- same sponsor
- different manufacturers
- same GMDN code
- same classification
Therefore not the same kind of medical device and
separate notifications required for each kind.
Again, do not need to notify TGA for each patient, only
the kind of device.
ADIA industry briefing 12-13 July 2016
11
13. Regulatory obligations
Who has obligations?
• both the manufacturer and the sponsor have obligations
• requirements to:
- meet the essential principles (EPs) - this demonstrates the quality, safety and performance of the device
- apply a conformity assessment procedure - this generates evidence that the device complies with the EPs
- notify the TGA
- comply with advertising requirements
- report adverse events
But aren’t custom-made devices ‘exempt’?
• exempt from ARTG inclusion only
• all other obligations still apply
ADIA industry briefing 12-13 July 2016 12
14. Requirement to notify TGA
• since 2002, Australian manufacturers
and sponsors importing custom-made
medical devices into Australia have
been required to notify TGA about
certain details, e.g. name and
business address, description of the
‘kind of device’
• in February 2016 the regulations were
amended to introduce a two month
timeframe for notification to the TGA
• details in Regulation 10.3
ADIA industry briefing 12-13 July 2016 13
15. How to notify …
• simple web-based notification form
• quick and easy to complete and submit
• some fields mandatory
• within 2 months of the device being
manufactured in Australia or
first imported into Australia
www.tga.gov.au/custom-made-medical-devices
ADIA industry briefing 12-13 July 2016 14
22. Other regulatory obligations
Essential Principles
• Regulations Schedule 1, Part 1 (general principles) and Part 2 (principles about design and construction)
• manufacturer must meet the applicable essential principles
• sponsor must ensure device meets applicable essential principles
• some EPs may not apply to the device (e.g. if the custom-made medical device is not supplied in a sterile
state, the essential principles regarding sterility are not relevant and will not need to be met)
• some essential principles apply only to custom-made medical devices:
- information that must be provided with a medical device - an indication that the device has been custom-
made for a particular individual or health professional and is intended for use only by that individual or health
professional must be provided with a custom-made medical device
- instructions for use (if required) must include an indication that the device has been custom-made for a
particular individual or health professional and is intended for use only by that individual or health
professional
• there is an ‘essential principles checklist’ on TGA’s website which may be helpful (not mandatory)
ADIA industry briefing 12-13 July 2016 21
23. Other regulatory obligations
Conformity assessment procedures
The manufacturer is required to:
• prepare and sign a written statement containing specific information (detailed in the Regs sched 3 item 7.2)
• prepare documentation relating to the design, production and intended performance of the device
(and keep the documentation up-to-date)
• take all measures necessary to ensure that the manufacturing process results in the device complying
with the documentation mentioned above
• notify the TGA as soon as practicable of certain events that might lead (or might have led) to the death or
serious deterioration of the state of health of the patient or user, or caused the manufacturer to recover a
device that has been distributed. Examples of these events include malfunction, deterioration and inadequacy
in the design, production, labelling or instructions for use.
The sponsor is required to ensure that the manufacturer has applied the conformity assessment procedures.
ADIA industry briefing 12-13 July 2016 22
24. About the ‘statement’
Details to be included:
• name and business address of manufacturer
• information to identify the device
• statement that manufacturer intends device to be used only for a particular individual or health professional
• name of the individual or health professional
• name and business address of health professional that provided device specifications
• particular design characteristics or construction provided by health professional
• a statement that the device complies with the applicable essential principles, or a statement explaining which
essential principles it does not comply with and reasons for the non-compliance
Statement to be signed and dated by an authorised person (from the manufacturer) and kept up-to-date
ADIA industry briefing 12-13 July 2016 23
25. Therapeutic Goods Advertising Code 2015
General Principles
Section 4 sets out the key requirements including that therapeutic good advertisements “must not”:
• Mislead or be likely to mislead
• Arouse unrealistic expectations of product effectiveness
• Lead consumers to self-diagnosing, inappropriately treating or believing they have a serious disease
• Abuse consumers’ trust or exploit their lack of knowledge
• Encourage inappropriate or excessive use
• Claim that a good is guaranteed, certain, sure cure or that the goods are completely safe or harmless
• Be directed to minors (subject to exceptions)
https://www.legislation.gov.au/Details/F2015L01787
ADIA industry briefing 12-13 July 2016 24
27. Summary
• Both manufacturers and sponsors/suppliers of custom-made medical devices have obligations
• ‘Custom-made’ has a specific meaning and is defined in the regulatory framework (not customised/adapted)
• Custom-made devices have specific requirements for information to be supplied with the device
• Custom-made devices are exempt from ARTG inclusion, but other obligations still apply
• Timeframe for notifying TGA of custom-made devices is 2 months
- from initial manufacture (if manufactured in Australia)
- from initial importation/supply in Australia (if manufactured overseas)
• Notifying TGA is only one obligation – others include:
- device must meet essential principles
- device must have had conformity assessment procedure applied
- adverse events must be reported to TGA
ADIA industry briefing 12-13 July 2016 26
Editor's Notes
If a dental technician or prosthetist:
uses devices (raw materials) included on the ARTG in accordance with their intended purpose, then the technician/prosthetist is adapting devices for an individual and is neither a manufacturer or sponsor
uses devices (raw materials) included on the ARTG but not in accordance with their intended purpose, then they are manufacturing custom-made devices
uses raw materials not included on the ARTG, they are manufacturing custom-made medical devices
Examples:
an orthodontist uses a number of devices included on the ARTG (e.g. orthodontic metal bands, orthodontic springs, orthodontic archwire, etc) for the purpose intended by the manufacturer (i.e. to make braces for a specific individual) the orthodontist is adapting these devices for a specific individual (i.e. not a manufacturer)
a dental technician using a polymer-based dental material to make a denture base as detailed in the product’s IFU is adapting the material for a specific individual (not a manufacturer)
a dental prosthetist that uses an ARTG included dental crown resin (a composite material intended to be used for veneering metallic dental crowns) to make a hard denture base (i.e. not in accordance with the IFUs) is a making a custom-made device and meets the definition of a manufacturer.
Note: GMDN 61718 – Preformed dental crown, permanent
A prefabricated prosthetic device designed to function as a permanent artificial covering to partially or fully replace the damaged crown of a tooth. It is made of ceramic and polymer materials and may require minimal fashioning in situ during restorative work. It is available as a single prosthesis or multiple prostheses of various shapes and sizes, and may include one or more try-in prosthesis replicas and other devices intended to assist the restoration procedure (e.g. disposable prosthesis gauge).
Examples:
A legal entitiy in China that designs, produces, packages, labels with their own name and exports (including to Australia) pre-formed permanent crowns is a manufacturer.
An individual based in Canberra imports large numbers of dental implant template retention pins that are manufactured in Germany, but packages the dental pins into smaller units, labels the packaging with their own names and supplies/sells the dental pins to other dental laboratories in Australia (or overseas) is a manufacturer and sponsor.
A dental laboratory based in Melbourne that:
imports (from overseas) non ARTG included polymer material, dental implant template retention pins and other items necessary for their dental technicians to produce dental crowns (in accordance with specifications provided by a dentist) – is a manufacturer of custom-made devices
and also packages, labels and sells the crowns to other dental laboratories –is a manufacturer and sponsor.
In order to be legally supplied in Australia, most medical devices must be included in the ARTG. This is where custom-made medical devices differ. Custom-made medical devices do not need to be included in the ARTG but they must still meet the other requirements, i.e. quality, safety and performance.
Several means by which ‘unauthorised medical devices’ (i.e. those not included in the ARTG) can be legally supplied in Australia:
custom-made medical devices
clinical trials scheme
authorised prescriber scheme
special access scheme
Custom-made medical devices do not need to be included in the ARTG but must comply with all other obligations.
In this instance, like many others, the functions of the Secretary of the Department of Health have been delegated to officers within the TGA.
Therefore ‘give the following information to the Secretary’ means give the info to the TGA.
The Regulations were amended in early 2016 following requests from the dental industry bodies:- in recognition that the majority of people in the industry want to comply with the regulatory obligations- to clarify the timeframe of the obligation to notify- in addition, TGA provided a simple means of notification, i.e. the web-based notification/reporting form
If the custom-made device is manufactured in Australia, the Australian manufacturer must notify the TGA
If the custom-made device is imported into Australia by a dentist, dental laboratory, etc but is manufactured overseas, the sponsor must notify the TGA (i.e. whoever imports and supplies the device in Australia – and this includes supplying/implanting/affixing it to a patient)
Select manufacturer or sponsor.
In some circumstances this is the same entity. TGA is planning to amend the form so that this option is available.
The first example demonstrates how a manufacturer will complete the form, i.e. an Australian manufacturer (manufacturers located overseas are not required to notify TGA – in this instance the obligation to notify is transferred to the Australian sponsor who imports and supplies).
The mandatory fields are simple details:
Manufacturer’s name and business address
Sponsor’s name and address
Brief description of the device
Classification of the device
Note that GMDN code is not a mandatory field. Codes are available through GMDN Agency membership (cost involved) or through TGA Business Services (must have client id and mock up an ARTG application).
Other non-mandatory details include contact info (email and phone) which TGA may need to use in case of post-market activities or recalls .
This is the page you will see once you have successfully completed a notification.
You can immediately download a copy of the completed form or have a copy emailed to any address you enter here (may or may not be the same email address you gave when you completed the form – either way you will need to enter the email address here).
If you nominate to have an emailed version sent to you, this is the email you will receive. Note that the completed form is an attachment ….
This is the view you will see once you open the attachment. Again you can save a copy of this if you choose.
The form has some additional fields for completion if you are a sponsor.
You will need to include the manufacturer’s details (often an overseas manufacturer, but may be an Australian manufacturer) as well as your own details as the sponsor.
Just like we saw when an Australian manufacturer completes the notification, the sponsor receives the same option to download a copy of the completed form or receive it as an attachment to an email.
Question: does an Australian manufacturer of custom-made medical devices need to notify if they only export?
Answer: Not explicitly required but the intention of the legislation appears to be for application to custom-made devices that will be supplied in Australia. However, this could be interpreted to apply to export-only also.
Notifying TGA about the manufacture or importation of custom-made medical devices is one of several obligations which the Australian manufacturer and sponsor are required to meet/satisfy.
Essential principles – demonstrate the quality, safety and performance of the device – this is especially important if the device is manufactured overseas (if manufactured in Australia the manufacturer will also be notifying TGA and meeting the essential principles)
Conformity assessment procedure – a procedure that generates the evidence that the device complies with the essential principles
Prepare and keep up to date a statement about the device
Comply with advertising requirements
Report adverse events
Chapter 4 of the Act details penalties for importing, supplying or exporting a medical device that does not comply with the essential principles:- s41MA lists criminal offences – 12 months prison or fine or both
- s41MAA lists civil offences – fines for individuals and bodies corporate
Importing and supplying and exporting
A person commits an offence if the person imports/supplies/exports a device and: - use of the device has resulted in harm or injury to any person- use of the device will result in harm or injury to any person- use of the device would be likely to result in harm or injury to any person- the harm or injury is because the devices does not comply with the essential principles (other than labelling)and- the secretary has not consulted to the importation/supply/export and the device is not of a kind covered by an exemption (i.e. national interest such as for stockpiling for emergency preparedness or to deal with an actual threat to public health caused by an emergency)Penalty: imprisonment for 12 months or a fine (or both)
If the Australian sponsor is supplying a product that was manufactured overseas, then the sponsor/supplier is taking responsibility for the device and making assurances that it is manufactured in accordance with the essential principles (i.e. it is of appropriate quality, is safe and will perform as intended).
The manufacturer must prepare the statement and keep it up-to-date, but there is no need to provide it to TGA unless requested.
Object of the Advertising Code
To ensure that the marketing and advertising of therapeutic goods to consumers is conducted in a manner that promotes the quality use of therapeutic goods, is socially responsible and does not mislead or deceive the consumer
Assessed in terms of probable impact upon a reasonable person to whom the advertisement is directed.
Advertising Tips
Hold the appropriate level of evidence
Claims must be consistent with intended purpose
No references to prohibited or unapproved restricted representations, “TGA approved” or to the product being safe
Endorsements and testimonials must comply fully with the Code
Include mandatory warning statements
Advertising Complaints
Complaints about medical device advertisements directed to the public that do not comply with the advertising requirements can be made to the:
Complaints Resolution Panel – TV, radio, newspapers, magazines, cinemas, posters
Medical Technology Association of Australia – in-store material, brochures
Therapeutic Goods Administration
Complaints considered by the Complaints Resolution Panel may result in the advertiser being requested to take certain actions.
The Panel may make a recommendation to the Secretary of the Department of Health (TGA) where the Advertiser fails to respond, or fails to indicate an intention to comply fully with Panel’s requests.
Again, the Secretary has delegated this function to officers within the TGA.
We commonly refer to these occurrences as post-market issues or adverse events.
Note that the manufacturer and sponsor have obligations to report adverse events to the TGA and the Regulations provide penalties if this is not done within prescribed timeframes.
The Regulations also state the manufacturer must notify the TGA as soon as practicable after becoming aware of:(a) an information relating to: (i) any malfunction or deterioration in the characteristics or performance of the device (ii) any inadequacy in the design, production, labelling or instructions for use of the device (iii) any use in accordance with, or contrary to, the used intended by the manufacturer of the device that might lead, or might have led, to the death of a patient or a user of the device, or to a serious deterioration in his or her state of health (b) information relating to any technical or medical reason for a malfunction or deterioration of the kind mentioned above that has lead the manufacturer to take steps to recover a device that has been distributed